KHCM
IPSC icon

Kettle Hill Capital Management’s Century Therapeutics IPSC Stock Holding History

Kettle Hill Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-54,100
Closed -$535K – 61
2022
Q3 		$535K Buy
+54,100
New +$570K 0.13% 54

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Kettle Hill Capital Management's IPSC Position: Q4 2022 in Review

Kettle Hill Capital Management sold out of Century Therapeutics (IPSC) in Q4 2022, closing a stake of 54,100 shares — an estimated $535K sold.

Kettle Hill Capital Management first reported a position in IPSC in Q3 2022 and held it in 1 quarter. The position peaked at $535K in Q3 2022. 65 funds tracked by Wall St. Rank hold IPSC as of Q4 2022.

  • Kettle Hill Capital Management reported no remaining Century Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kettle Hill Capital Management sold 54,100 Century Therapeutics shares in Q4 2022, an estimated $535K.
  • Kettle Hill Capital Management first reported a position in Century Therapeutics in Q3 2022 and held it in 1 quarter.
  • Kettle Hill Capital Management's Century Therapeutics position peaked at $535K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2022.

Based on Kettle Hill Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.